Hershel Jick1, Katrina Wilcox Hagberg, Pascal Egger. 1. Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, Lexington, Massachusetts 02421, USA. hjick@bu.edu
Abstract
STUDY OBJECTIVE: To estimate the rate of suicide in patients taking montelukast. DESIGN: Population-based cohort study. DATA SOURCE: United Kingdom General Practice Research Database. PATIENTS: A total of 23,500 patients who had received at least one prescription for montelukast in the cumulative data from February 1998-March 2007. MEASUREMENTS AND MAIN RESULTS: Rate of suicide was to be calculated as number of suicides divided by person-time at risk. Person-time of montelukast exposure was accrued for each patient as a cumulative duration of all prescriptions. The 23,500 patients had received 252,593 prescriptions for montelukast, representing 21,050 person-years at risk for suicide. We then sought to identify all cases that had a computer-recorded diagnosis of suicide; however, no cases of suicide were found in patients exposed to montelukast during our time frame. CONCLUSION: The risk of suicide attributable to montelukast, if present at all, is extremely low in users.
STUDY OBJECTIVE: To estimate the rate of suicide in patients taking montelukast. DESIGN: Population-based cohort study. DATA SOURCE: United Kingdom General Practice Research Database. PATIENTS: A total of 23,500 patients who had received at least one prescription for montelukast in the cumulative data from February 1998-March 2007. MEASUREMENTS AND MAIN RESULTS: Rate of suicide was to be calculated as number of suicides divided by person-time at risk. Person-time of montelukast exposure was accrued for each patient as a cumulative duration of all prescriptions. The 23,500 patients had received 252,593 prescriptions for montelukast, representing 21,050 person-years at risk for suicide. We then sought to identify all cases that had a computer-recorded diagnosis of suicide; however, no cases of suicide were found in patients exposed to montelukast during our time frame. CONCLUSION: The risk of suicide attributable to montelukast, if present at all, is extremely low in users.
Authors: Glen T Schumock; Todd A Lee; Min J Joo; Robert J Valuck; Leslie T Stayner; Robert D Gibbons Journal: Drug Saf Date: 2011-07-01 Impact factor: 5.606
Authors: Kyla H Thomas; Richard M Martin; John Potokar; Munir Pirmohamed; David Gunnell Journal: BMC Pharmacol Toxicol Date: 2014-09-30 Impact factor: 2.483